Animals and Tumor Models. All animal studies were performed in compliance with the guidelines set by Tianjin Committee of Use and Care of Laboratory Animals and the overall project protocols were approved by the Animal Ethics Committee of Nankai University. All the mice were purchased from Laboratory Animal Center of the Academy of Military Medical Sciences (Beijing, China). To set up peritoneal carcinomatosis-bearing mouse model, a total of 300,000 luciferaseexpressed 4T1 cancer cells in 0.1 mL of PBS buffer were intraperitoneally injected into the Balb/c mice. After 5 days, small tumor nodules were formed and scattered in the mouse peritoneal cavity, which could be detected by bioluminescence imaging upon injection of a solution of D-luciferin (150 mg/kg).
Study on Evaluation of
In Vivo Toxicity. Healthy BALB/c mice were randomly assigned to 2 groups and each group contained 4 mice. On day 0, the mice in one group were intravenously injected with 100 µL of AIE NPs (100 nM). After the injection, 9 day follow-up experiments were conducted, in which the weights of all the mice in two groups were scrutinized. On day 9, the mice in two groups were sacrificed and the blood was collected through cardiac puncture at the time of sacrifice for blood chemistry analyses by Tianjin First Central Hospital.
Surgery with AIE NP Fluorescence Guidance. The mice bearing peritoneal carcinomatosis were intravenously injected with 100 µL of AIE NPs (50 nM). At 24 h post-injection, the mice were anesthetized. The abdomen or thoracic cavity of mice was opened, followed by bioluminescence and fluorescence imaging during surgery. The excised tumor nodules were analyzed by both imaging modalities. Alternatively, the surgery was performed by the experience of a surgeon without imaging guidance (unguided). Bioluminescence imaging was performed using the Xenogen IVIS ® Lumina II system post intraperitoneal injection of D-luciferin (150 mg/kg) into the mice. The bioluminescence signals were quantified in units of maximum photons per second per square centimeter per steridian. On the other hand, fluorescence imaging was carried out using a Maestro EX in vivo fluorescence imaging system (CRi, Inc.) . The light with a central wavelength at 635 nm was selected as the excitation source. In vivo spectral imaging from 670 nm to 900 nm in 10 nm steps was conducted with an exposure time of 150 ms for each image frame. The original fluorescence images contained both signal and mouse autofluorescence were shown, which were not post-processed by any softwares such as unmixing function of Maestro software to remove the background fluorescence.
Statistical Analysis. Quantitative data were expressed as mean ± standard deviation. Statistical comparisons were made by ANOVA analysis and Student's t-test. P value < 0.05 was considered statistically significant.
Synthesis of α-DTPEBBTD-Cx and β-DTPEBBTD-Cx
(4-Bromophenyl)(4-methoxyphenyl)methanone (1). To a solution of 4-bromobenzoyl chloride (2.17 g, 10.0 mmol) and aluminum chloride (1.36 g, 10.2 mmol) in dry dichloromethane (15 mL) under argon atmosphere was added anisole (3.26 mL, 30 mmol) in an ice bath. The mixture was kept at 0~10 o C for 1 h and then stirred at room temperature overnight. Hydrochloric acid aqueous solution (100 mL, 1 M) was carefully added into the reaction mixture in ice bath to yield precipitates. After filtration under reduced pressure, the obtained solid was further purified by silica gel column chromatography using a mixture of hexane/ethyl acetate (9/1) as eluent to give (4-bromophenyl)(4-methoxyphenyl)methanone as a white solid. 1 H NMR (400 MHz, CDCl 3 , ppm) δ 7. 81-7.78 (m, 2 H), 7.65-7.62 (m, 4 H), 6.98-6.95 (m, 2 H) , 3.89 (s, 3 H). 13 C NMR (100 MHz, CDCl 3 , ppm) δ 194. 5, 163.6, 137.2, 132.6, 131.6, 131.4, 129.9, 127.0, 113.8, 55.7. 1-(4-Bromophenyl)-2,2-diphenyl-1-(4-methoxyphenyl)ethene (2). Diphenylmethane (2.02 g, 12.0 mmol) in anhydrous THF (50 mL) was stirred at 0 o C under argon atmosphere, then n-BuLi (1.6 M in hexane, 6.87 mL, 11.0 mmol) was added dropwise into the mixture. The resultant red mixture was kept at 0 o C for 1 h, then a solution of compound 1 (2.91 g, 10 mmol) in anhydrous THF (10 mL) was added slowly. The reaction mixture was stirred at room temperature overnight.
After treatment with a saturated NH 4 Cl aqueous solution, the crude product was extracted with dichloromethane (50 mL × 3). The combined organic phase was sequentially washed with water, dried over MgSO 4 and filtered. After solvent removal, the residue and p-toluenesulfonic acid (86.0 mg, 0.5 mmol) were treated in toluene (25 mL) at 100 o C for 3 h. The crude product was sequentially extracted with dichloromethane (50 mL × 3), washed with water (100 mL × 3), and dried over MgSO 4 . After solvent removal, the residue was purified by silica gel column chromatography (hexane/dichloromethane/ethyl acetate = 8/2/0.2) to yield compound 2 as a white solid (3.48 g, yield: 79%). 1 H NMR (400 MHz, CDCl 3 , ppm) δ 7.23-7.22 (m, 2 H), 7.14-7.10 (m, 6 H), 7.04-7.01 (m, 4 H), 6.93-6.90 (m, 4 H), 6.66-6.64 (m, 2 H), 3.75 (s, 3 H). 13 C NMR (100 MHz, CDCl 3 , ppm) δ 158. 38, 143.86, 143.71, 143.11, 140.85, 139.37, 135.71, 133.17, 132.64, 131.41, 131.36, 130.93, 127.97, 127.88, 126.65, 126.56, 120.49, 113.31, 55.24. 2,2-Diphenyl-1-(4-bromophenyl)-1-(4-hydroxyphenyl)ethene (3). To a solution of compound 2 (3.53 g, 8.0 mmol) in anhydrous dichloromethane (20 mL) under argon atmosphere was slowly added boron tribromide solution (1 M in dichloromethane, 10.5 mL, 10.5 mmol) at -78 o C. Then the reaction mixture was stirred at room temperature overnight. After quenching with ice water, the crude product was sequentially extracted with dichloromethane (50 mL × 3), washed with water (100 mL × 3), dried over Na 2 SO 4 and filtered. After solvent removal, the residue was purified by silica gel column chromatography (hexane/dichloromethane = 3/7) to afford compound 3 as a light green solid (2.0 g, yield: 91% 42, 143.83, 143.64, 143.00, 140.90, 139.32, 135.84, 133.14, 132.82, 131.38, 131.33, 130.93, 127.96, 127.87, 126.67, 126.56, 120.51, 114.88. 2,2-Diphenyl-1-(4-bromophenyl)-1-(4-butoxyphenyl)ethene (4a). To a mixture of compound 3 (852.0 mg, 2.0 mmol) and cesium carbonate (Cs 2 CO 3 , 975.0 mg, 3.0 mmol) in anhydrous dimethylformamide (DMF, 5.0 mL) was added 1-bromobutane (0.32 mL, 3.0 mmol) under argon atmosphere. The reaction mixture was stirred at room temperature overnight. After quenching with water, the crude product was sequentially extracted with dichloromethane (30 mL × 3), washed with water (50 mL × 3), and dried over MgSO 4 . After solvent removal, the residue was further purified by silica gel column chromatography (hexane/dichloromethane = 9/1) to give compound 4a as a light green fibrous solid (888.6 mg, yield: 92%). 1 H NMR (400 MHz, CDCl 3 , ppm) δ 7.25-7.23 (m, 2 H), 7.14-7.10 (m, 6 H), 7.06-7.01 (m, 4 H), 6.94-6.90 (m, 4 H), 6.67-6.62 (m, 2 H), 3.91 (t, J = 8 Hz, 2 H), 1.76 (m, 2 H), 1.50 (m, 2 H), 0.98 (t, J = 8 Hz, 3 H). 13 C NMR (100 MHz, CDCl 3 , ppm) δ 158. 00, 143.90, 143.76, 143.15, 140.72, 139.45, 135.46, 133.20, 132.61, 131.42, 131.36, 130.91, 127.96, 127.87, 126.62, 126.52, 120.47, 113.83, 67.64, 31.49, 19.40, 14 .04.
2,2-Diphenyl-1-(4-octyloxyphenyl)-1-(4-bromophenyl)ethene (4b).
Compound 4b was obtained as viscous oil (948.6 mg, yield: 88%) using a similar synthetic procedure as compound 04, 143.93, 143.79, 143.18, 140.76, 139.50, 135.49, 133.20, 132.62, 131.43, 131.37, 130.92, 127.97, 127.88, 126.63, 126.53, 120.48, 113.88, 68.02, 31.96, 29.52, 29.44, 29.36, 26.20, 22.80, 14.23. 1,2-Diphenyl-2-(4-methoxyphenyl)-1-(4-trimethylstannylphenyl)ethane (5a). To a solution of compound 2 (441.0 mg, 1.0 mmol) in anhydrous THF (10 mL) at -78 o C under argon atmosphere was slowly added n-BuLi (1.6 M in hexane, 0.93 mL, 1.5 mmol). After the reaction mixture was stirred at -78 o C for 1.5 h, trimethyltin chloride (Me 3 SnCl, 1.0 M in THF, 1.8 mL)
was added to the mixture in one portion. Then it was slowly warmed to room temperature and stirred overnight. The mixture was poured into water and extracted with dichloromethane (30 mL × 3). The combined organic layer was sequentially washed with water (100 mL × 3), dried over Na 2 SO 4 , and filtered. After solvent removal, the residue was obtained as colorless liquid and used directly in the next step without further purification.
2-(4-Butoxyphenyl)-1,2-diphenyl-1-(4-trimethylstannylphenyl)ethane (5b). Compound 5b
was synthesized using a similar synthetic procedure as compound 5a, starting from compound 4a (483.0 mg, 1.0 mmol), n-BuLi (1.6 M in hexane, 0.93 mL, 1.5 mmol), Me 3 SnCl (1.0 M in THF, 1.8 mL) and anhydrous THF (15 mL). The obtained colorless liquid was used directly in the next step without further purification.
1,2-Diphenyl-2-(4-octyloxyphenyl)-1-(4-trimethylstannylphenyl)ethane (5c). Compound 5c
was synthesized using a similar synthetic procedure as compound 5a, starting from compound 4b (539.0 mg, 1.0 mmol), n-BuLi (1.6 M in hexane, 0.93 mL, 1.5 mmol), Me 3 SnCl (1.0 M in THF, 1.8 mL) and anhydrous THF (15 mL). The obtained colorless liquid was used directly in the next step without further purification. 01, 152.91, 144.80, 144.29, 144.08, 141.11, 140.39, 135.96, 133.28, 132.90, 131.63, 131.56, 131.51, 131.32, 127.97, 127.85, 126.64, 126.46, 121.11, 113.88, 67.69, 31.54, 19.41, 14 .02. 01, 152.92, 144.81, 144.30, 144.09, 141.11, 140.40, 135.96, 133.28, 132.90, 131.63, 131.56, 131.51, 131.33, 127.97, 127.85, 126.64, 126.46, 121.12, 113.90, 68.04, 31.96, 29.53, 29.48, 29.37, 26.22, 22.80, 14.23 . Bromophenyl)-2-(4-methoxyphenyl)-1,2-diphenylethane (6) . A two-necked round-bottom flask with a reflux condenser was charged with 4-bromobenzophenone (3.91 g, 15.0 mmol), 4-methoxybenzophenone (3.18 g, 15.0 mmol) and zinc (5.20 g, 80.0 mmol). The flask was degassed with three freeze-pump-thaw cycles to remove air, and then anhydrous THF (150 mL) was added.
1-(4-
The mixture was cooled to -78 o C and TiCl 4 (4.9 mL, 45.0 mmol) was added dropwise by a syringe. The reaction mixture was slowly warmed to room temperature and stirred for 0.5 h before it was heated to 80 o C for 24 h. After cooling down to room temperature, the reaction was quenched by the addition of 10% K 2 CO 3 aqueous solution (100 mL). The mixture was filtered off to remove insoluble materials and washed with dichloromethane (150 mL). The organic layer was dried over 132.4, 131.4, 131.3, 130.9, 130.8, 130.1, 128.4, 128.3, 127.8, 127.7, 127.6, 126.5, 126.4, 120.2, 113 .0, 55.6, 55.0.
1-(4-Bromophenyl)-2-(4-hydroxyphenyl)-1,2-diphenylethane (7).
Compound 7 was obtained as a light green solid (3.13 g, yield: 92%) using a procedure similar to that used for compound 3, starting from compound 6 (2.2 g, 5.0 mmol) and BBr 3 solution (1 M in dichloromethane, 7 mL, 7.0 mmol). 1 H NMR (400 MHz, CDCl 3 , ppm): δ 7.25-7.19 (m, 2 H), 7.14-6.98 (m, 10 H), 6.92-6.86 (m, 4 H), 6.60-6.55 (m, 2 H), 4.88 (d, 1H). 13 C NMR (100 MHz, CDCl 3 , ppm): δ 153. 66, 153.55, 142.93, 142.88, 142.85, 142.35, 142.26, 140.47, 138.24, 138.20, 135.38, 135.27, 132.36, 132.06, 132.04, 130.64, 130.27, 130.17, 127.22, 127.11, 127.02, 126.04, 125.94, 125.87, 119.63, 114 .18, 113.99. 157.80, 143.67, 143.60, 143.56, 143.47, 143.04, 142.98, 141.26, 138.63, 138.58, 135.39, 132.98, 132.43, 132.41, 132.38, 131.30, 131.27, 131.02, 130.91, 130.86, 130.75, 127.81, 127.70, 127.58, 126.48, 126.41, 120.45, 120.18, 113.78, 113.74, 113.57, 67.48, 67.44, 31.34, 31.32, 19.24, 13.89, 13 .87.
1-(4-Bromophenyl)-2-(4-butoxyphenyl)-1,2-diphenylethane (8a)
.
1-(4-Bromophenyl)-2-(4-butoxyphenyl)-1,2-diphenylethane (8b). Compound 8b was
synthesized using a similar synthetic procedure as compound 4a, starting from compound 7 (852.0 mg, 2 mmol), Cs 2 CO 3 (975.0 mg, 3 mmol), DMF (5.0 mL) and 1-bromooctane (0.52 mL, 3 mmol).
The crude product was purified by silica gel column chromatography (hexane/dichloromethane = 9/1) to give compound 8b as a light green fibrous solid (1.0 g, yield: 93%). 1 H NMR (400 MHz, 92, 157.83, 143.70, 143.63, 143.59, 143.50, 143.01, 141.28, 138.62, 135.53, 133.02, 132.49, 132.46, 132.43, 131.39, 131.33, 131.30, 130.89, 130.78, 127.84, 127.80, 127.72, 127.69, 127.61, 127.57, 126.61, 126.51, 126.43, 120.19, 113.77, 113.60, 67.91, 67.82, 31.82, 29.40, 29.38, 29.31, 29.30, 29.24, 29.23, 26.08, 26.07, 22.66, 14 .12.
Compounds 9a-c. Compounds 9a-c were synthesized using a similar procedure as compounds 5a-c, and used directly without further purification. 52, 152.87, 144.77, 144.16, 144.02, 141.63, 139.84, 136.18, 133.16, 132.80, 131.74, 131.58, 131.45, 131.40, 127.98, 127.86, 127.74, 126.60, 126.52, 121.03, 113.46, 55.25 . 12, 157.94, 152.91, 152.86, 152.83, 144.82, 144.76, 144.22, 144.16, 144.08, 141.72, 139.70, 136.07, 135.93, 133.13, 133.10, 132.78, 132.74, 131.77, 131.73, 131.66, 131.61, 131.43, 131.32, 127.97, 127.85, 127.71, 126.76, 126.58, 126.49, 125.65, 121.03, 113.98, 113.73, 67.98, 31.95, 31.91, 30.48, 29.52, 29.49, 29.45, 29.43, 29.37, 29.33, 26.21, 26.19, 22.80, 22.75, 14.24, 14.21 . 
β-DTPEBBTD-C1. Compound β-DTPEBBTD-C1
α-DTPEBBTD-C1 α-DTPEBBTD-C4 α-DTPEBBTD-C8 β-DTPEBBTD-C1 β-DTPEBBTD-C4 β-DTPEBBTD-C8
